Synthesis of benzothiazole derivatives and their biological evaluation as anticancer agents

Medicinal Chemistry Research

Volumn 21, Issue 9, 2012, Pages 2644-2651

  Caputo, Rosanna ^a   Calabrò, Maria Luisa ^a   Micale, Nicola ^a   Schimmer, Aaron D ^b   Ali, Moshin ^b   Zappalà, Maria ^a   Grasso, Silvana ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Anticancer activity; Benzothiazole derivatives; Synthesis

Indexed keywords

1 (2,6 DIFLUOROPHENYL) 3 (6 METHOXYBENZOTHIAZOL 2 YL)UREA; 1 (2,6 DIFLUOROPHENYL) 3 (6 TRIFLUOROMETHOXYBENZOTHIAZOL 2 YL)UREA; 1 (4 CYANOPHENYL) 3 (6 METHOXYBENZOTHIAZOL 2 YL)UREA; 1 (4 CYANOPHENYL) 3 (6 TRIFLUOROMETHOXYBENZOTHIAZOL 2 YL); 1 (4 FLUOROPHENYL) 3 (6 METHOXYBENZOTHIAZOL 2 YL)UREA; 1 (4 FLUOROPHENYL) 3 (6 TRIFLUOROMETHOXYBENZOTHIAZOL 2 YL)UREA; 1 (4 METHOXY) 3 (6 TRIFLUOROMETHOXYBENZOTHIAZOL 2 YL)UREA; 1 (4 METHOXYPHENYL) 3 (6 METHOXYBENZOTHIAZOL 2 YL)UREA; 2 AMINO 6 METHOXYBENZOTHIAZOLE; 2,6 DIFLUORO N (6 METHOXYBENZOTHIAZOL 2 YL)BENZAMIDE; 2,6 DIFLUORO N (6 TRIFLUOROMETHOXYBENZOTHIAZOL 2 YL)BENZAMIDE; 4 ACETYLAMINO N (6 METHOXYBENZOTHIAZOL 2 YL)BENZAMIDE; 4 ACETYLAMINO N (6 TRIFLUOROMETHOXYBENZOTHIAZOL 2 YL)BENZAMIDE; 4 CYANO N (6 METHOXYBENZOTHIAZOL 2 YL)BENZAMIDE; 4 CYANO N (6 TRIFLUOROMETHOXYBENZOTHIAZOL 2 YL)BENZAMIDE; 4 FLUORO N (6 METHOXYBENZOTHIAZOL 2 YL)BENZAMIDE; 4 FLUORO N (6 TRIFLUOROMETHOXYBENZOTHIAZOL 2 YL)BENZAMIDE; 4 METHOXY N (6 METHOXYBENZOTHIAZOL 2 YL)BENZAMIDE; 4 METHOXY N (6 TRIFLUOROMETHOXYBENZOTHIAZOL 2 YL)BENZAMIDE; ANTINEOPLASTIC AGENT; BENZOTHIAZOLE DERIVATIVE; FLUOROURACIL; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER INHIBITION; CENTRAL NERVOUS SYSTEM TUMOR; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY CANCER; LEUKEMIA; LUNG NON SMALL CELL CANCER; MELANOMA; OVARY CANCER; PROSTATE CANCER;

EID: 84866431016     PISSN: 10542523     EISSN: 15548120     Source Type: Journal    
DOI: 10.1007/s00044-011-9789-8     Document Type: Article

References (16)

1. Aiello S, Wells G, Stone EL, Kadri H, Bazzi R, Bell DR, Stevens MFG, Matthews CS, Bradshaw TD, Westwell AD (2008) Synthesis and biological properties of benzothiazole, benzoxazole, and chromen-4-one analogues of the potent antitumor agent 2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole (PMX 610, NSC 721648). J Med Chem 51:5135-5139
2. Boyd MR (1997) Preclinical screening, clinical trials, and approval. Humana Press, Totowa, NJ
3. Boyd MR, Paull KD (1995) Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen. Drug Dev Res 34:91-109
4. Brantley E, Antony S, Kohlhagen G, Meng LH, Agama K, Stinson SF, Sausville EA, Pommier Y (2006) Anti-tumor drug candidate 2-(4-amino-3- methylphenyl)-5-fluorobenzothiazole induces single-strand breaks and DNA-protein cross-links in sensitive MCF-7 breast cancer cells. Cancer Chemother Pharmacol 58:62-72
5. Das J, Moquin RV, Lin J, Liu C, Doweyko AM, DeFex HF, Fang Q, Pang S, Pitt S, Shen DR, Schieven GL, Barrish JC, Wityak J (2003) Discovery of 2-amino-heteroaryl-benzothiazole-6-anilides as potent p56lck inhibitors. Bioorg Med Chem Lett 13: 2587-2590 (Pubitemid 36830779)
6. Gue'dat P, Colland F (2007) Patented small molecule inhibitors in the ubiquitin proteasome system. BMC Biochemistry 8(Suppl 1): S14
7. Jimonet P, Audiau F, Barreau M, Blanchard JC, Boireau A, Bour Y, Cole'no MA, Doble A, Doerflinger G, Huu GD, Donat MH, Duchesne JM, Ganil P, Guérémy C, Honoré H, Just B, Kerphirique R, Gontier S, Hubert P, Laduron PM, Le Blevec J, Meunier M, Miquet JM, Nemecek C, Pasquet M, Piot O, Pratt J, Rataud J, Reibaud J, Stutzmann JM, Magnani S (1999) Riluzole series. Synthesis and in vivo "antiglutamate" activity of 6-substituted-2-benzothiazolamines and 3-substituted-2-iminobenzothiazolines. J Med Chem 42:2828-2843 (Pubitemid 29370427)
8. Lion CJ, Matthews CS, Wells G, Bradshaw TD, Stevens MFG, Westwell AD (2006) Antitumour properties of fluorinated benzothiazole-substituted hydroxycyclohexa-2,5-dienones ("quinols"). Bioorg Med Chem Lett 16:5005-5008 (Pubitemid 44255890)
9. Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, Hose C, Langley J, Cronise P, Vaigro-Wolff A, Gray-Goodrich M, Campbell H, Mayo J, Boyd M (1991) Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 83:757-766
10. Mortimer CG, Wells G, Crochard JP, Stone EL, Bradshaw TD, Stevens MFG, Westwell AD (2006) Antitumor benzothiazoles. 26. 2-(3,4-Dimethoxyphenyl)-5- fluorobenzothiazole (GW 610, NSC 721648), a simple fluorinated 2-arylbenzothiazole, shows potent and selective inhibitory activity against lung, colon, and breast cancer cell lines. J Med Chem 49:179-185
11. Parlati F, Ramesh UV, Singh R, Payan DG, Lowe R, Look GC Benzothiazole and thiazole[5,5-b] pyridine compositions and their use as ubiquitin ligase inhibitors Publication No. WO 2005/037845
12. Sankaranarayanan A, Raman G, Busch C, Schultz T, Zimin PI, Hoyer J, Kohler R, Wulff H (2009) Naphtho[1, 2-d] thiazol-2-ylamine (SKA-31), a new activator of KCa2 and KCa3.1 potassium channels, potentiates the endothelium-derived hyperpolarizing factor response and lowers blood pressure. Mol Pharmacol 75:281-295
13. Song EY, Kaur N, Park MY, Jin Y, Lee K, Kim G, Lee KY, Yang YS, Shin JH, Nam KY, No KT, Ha G (2008) Synthesis of amide and urea derivatives of benzothiazole as Raf-1 inhibitor. Eur J Med Chem 43:1519-1524 (Pubitemid 351885223)
14. Wells G, Bradshaw TD, Diana P, Seaton A, Shi D, Westwell AD, Stevens MFG (2000) Antitumour benzothiazoles. Part 10: The synthesis and antitumour activity of benzothiazole substituted quinol derivatives. Bioorg Med Chem Lett 10:513-515 (Pubitemid 30153625)
15. Xu GW, Ali M, Wood TE, Wong D, Maclean N, Wang X, Gronda M, Skrtic M, Li X, Hurren R, Mao X, Venkatesan M, Beheshti Zavareh R, Ketela T, Reed JC, Rose D, Moffat J, Batey RA, Dhe-Paganon S, Schimmer AD (2010) The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma. Blood 115:2251-2259
16. Yoshida M, Hayakawa I, Hayashi N, Agatsuma T, Oda Y, Tanzawa F, Iwasaki S, Koyama K, Furukawa H, Kurakata S, Sugano Y (2005) Synthesis and biological evaluation of benzothiazole derivatives as potent antitumor agents. Bioorg Med Chem Lett 15:3328-3332 (Pubitemid 40835729)